{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009886","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.177021+00:00","generated_at":"2026-05-16T10:50:20.254327+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Soleno reports preliminary FY2025 VYKAT XR revenue $189M-$191M; profitable","bullets":["Preliminary Q4 2025 net revenue $90M-$92M; full-year net revenue $189M-$191M.","1,250 patient start forms since launch (207 in Q4), ~12.5% of U.S. PWS addressable market.","630 unique prescribers, 136 new in Q4; discontinuation rate ~12% for adverse events.","Achieved profitability and positive cash flow; year-end cash ~$500M after $100M buyback.","Company responded to EMA Day 120 questions; ~60% of total lives covered."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009886","json":"https://secwatch.observer/filing/0001193125-26-009886.json","markdown":"https://secwatch.observer/filing/0001193125-26-009886.md","text":"https://secwatch.observer/filing/0001193125-26-009886.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526009886/0001193125-26-009886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526009886/d18767d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:50:20.254327+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}